Advertisement
HIV resistance to the antiretroviral drug tenofovir (Viread) is common

High Level of Tenofovir Resistance for Those With HIV

0
Resistance affects almost two-thirds of those taking tenofovir in sub-Sahara Africa
Zepatier (elbasvir and grazoprevir) has been approved by the U.S. Food and Drug Administration to treat chronic hepatitis C virus genotypes 1 and 4 infections.

FDA Approves Zepatier for Chronic Hepatitis C

0
Medication indicated for patients with hepatitis C virus genotypes 1 and 4 infections
For patients hospitalized with acute myocardial infarction (AMI)

n-3 PUFA Tx After AMI Linked to Drop in Death, Recurrent AMI

0
Treatment linked to reduction in all-cause mortality, recurrent acute MI though 12-month follow-up
For patients with John Cunningham virus (JCV)

Tysabri Impacts Seroconversion in John Cunningham Virus

0
Over 14.8 months, natalizumab treatment linked to 15.9 percent increase of value in JCV+ patients
For warfarin-treated patients

Carbamazepine Affects Warfarin Anticoagulation

0
Carbamazepine co-treatment linked to subtherapeutic anticoagulative effect of warfarin
Halaven (eribulin mesylate) has been approved by the U.S. Food and Drug Administration as the first chemotherapy drug shown to improve survival in people with advanced liposarcoma.

FDA Approves Halaven for Advanced Liposarcoma

0
FDA says it's first liposarcoma drug to improve survival
For patients with nonvalvular atrial fibrillation

Review: Dabigatran Comparable to Warfarin for Nonvalvular A-Fib

0
Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding
From 2008 to 2014 there was an increase in drug shortages within the scope of emergency medicine practice

Drug Shortages Affecting Emergency Med Up 2008 to 2014

0
Increases seen in drugs used as direct lifesaving intervention or for high acuity conditions
There's been speculation that a daily vitamin D supplement taken in pregnancy might lower the odds for asthma in children. However

Prenatal Vitamin D Supplements Don’t Reduce Asthma

0
No evidence of beneficial effect on asthma, chronic wheezing in two studies
A single intravenous cyclosporine A bolus just before primary percutaneous coronary intervention has no beneficial effects on ST-segment resolution in reperfused myocardial infarction

No Beneficial Effects Seen for Cyclosporine A in Reperfused MI

0
Does not improve ST-segment resolution, hs-cTnT, clinical outcomes, or LV remodeling